We have investigated functional outcome of challenging primary chronic myeloid leukaemia (CML) cells with Bcr-Abl fusion sequence-directed RNA interference (RNAi). We targeted the Bcr-Abl b3a2 variant, by RNAi, in primary chronic phase CML cells, and detected strikingly reduced proliferation of myeloid precursor cells expressing this variant. Lack of an effect in cells expressing a distinct Bcr-Abl variant confirmed the specificity of the response. Through the functional targeting of an oncogene in primary human tumour cells, we have demonstrated that Bcr-Abl enhances CML progenitor cell amplification, and that RNAi may be suitable for development as a specific anti-leukaemia treatment. © 2005 Blackwell Publishing Ltd.
CITATION STYLE
Withey, J. M. E., Marley, S. B., Kaeda, J., Harvey, A. J., Crompton, M. R., & Gordon, M. Y. (2005). Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. British Journal of Haematology, 129(3), 377–380. https://doi.org/10.1111/j.1365-2141.2005.05468.x
Mendeley helps you to discover research relevant for your work.